{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Communication Frameworks in Palliative Surgical Scenarios"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to view two videos depicting a physician-patient encounter using either the BC/WC or R/B framework."
      },
      "Participants": {
        "score": 2,
        "evidence": "66 patients with advanced cancer."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to view two videos depicting a physician-patient encounter using either the BC/WC or R/B framework."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine if patients with advanced cancer prefer the best case/worst case (BC/WC) communication framework over the traditional risk/benefit (R/B) framework in palliative surgical scenarios."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the patients' preferred communication framework."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Both patients and outcome assessors were blinded to the intervention."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Conducted from November 2020 to May 2021, this double-blinded, video vignette-based randomised controlled trial involved 66 patients with advanced cancer."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 66 randomised, 58 completed the study"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "22 patients (37.9%, 95%CI:25.4%\u221250.4%) preferred the BC/WC framework, 21 (36.2%, 95%CI:23.8%\u221248.6%) preferred the R/B framework, and 15 (25.9%, 95%CI:14.6%\u221237.2%) had no preference."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}